基于树的分析揭示了患者衍生器官药物反应的结构调节
María Ramos Zapatero1, Alexander Tong2, James W Opzoomer1
1Cell Communication Lab, Department of Oncology, University College London Cancer Institute, London WC1E 6DD, UK.
Cell
|December 8, 2023
概括
我们开发了一个质量细胞测量平台和分析方法来研究结肠直肠癌 (CRC) 器官及其微环境. 这揭示了癌症相关纤维细胞 (CAF) 如何通过改变干细胞状态来保护CRC细胞免受化疗.
科学领域:
- 癌症学
- 生物技术
- 细胞生物学
背景情况:
- 患者衍生器官 (PDO) 对于个性化癌症治疗反应的建模具有价值.
- 目前的查方法不足以揭示药物机制或瘤微环境细胞对治疗结果的影响.
研究的目的:
- 开发一个高通量平台,用于分析结直肠癌 (CRC) PDO及其相关结构细胞的药物反应机制.
- 研究癌症相关纤维细胞 (CAF) 对CRC细胞可塑性和治疗耐药性的影响.
主要方法:
- 使用高度多重化的质量细胞测量平台来评估2500个CRC PDO和CAF的转化后修饰 (PTM) 信号,DNA损伤,细胞周期状态和细胞亡.
- 开发了一种可扩展的基于树的分析方法"Trellis",用于在单细胞分辨率下比较患者和微环境特异性药物反应.
主要成果:
- 单细胞查发现了常见的目标药物效应,如细胞循环阻塞和DNA损伤,甚至在耐药的PDO中.
- 发现药物诱导的亡较为罕见,患者特异,与癌细胞PTM信号相关.
- 证明CAF可以诱导CRC干细胞的可塑性,将其从增殖性 (proCSCs) 转移到缓慢循环状态 (revCSCs),从而赋予化疗耐药性.
结论:
- 开发的平台和特雷利斯方法可以对复杂的瘤微环境中的药物反应进行深入的机械洞察.
- 了解CAF介导的保护机制对于开发抗化疗结直肠癌的新疗法至关重要.
相关概念视频
Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...


